PhD defence A. Adhyatmika
|When:||Fr 30-11-2018 14:30 - 15:30|
Osteoprotegerin in fibrotic disorders
The work presented by Adhy Adhyatmika has shown that the activity spectrum of osteoprotegerin (OPG) and RANKL is far wider than just modulating bone matrix and has also shown exciting new avenues to treat and diagnose liver fibrosis and possibly to stimulate liver regeneration.
Serum levels of TNFRSF11B, also known as the decoy receptor OPG, were added to a panel of serum markers that have some potential in diagnosing liver fibrosis (Coopscore©). Moreover, a few studies have shown possible profibrotic activities of OPG, especially through interaction with its ligands RANKL and TRAIL. However, why OPG is produced during liver fibrosis and what its function could be in liver tissue is unknown. We therefore set out to elucidate why OPG is produced during fibrosis and by which tissues and what its biological activity is in human and mouse livers during the development and resolution of liver fibrosis.We propose OPG as a novel potential target for liver fibrosis treatment. A deeper and broader understanding of the possible profibrotic mechanisms of OPG will be essential to develop it further as a target for antifibrotic therapy. Its role in bone protection is unequivocal and must be taken into account when considering it as a target for therapy. Further research should also focus on the RANKL/OPG balance. The role of RANKL in liver tissue is understudied, but potentially interesting as it may stimulate regeneration of liver tissue.Promotores: Dr. B.N. Melgert and Prof.dr. K. Poelstra